PROSPECTUS SUPPLEMENT	Filed Pursuant to Rule 424(b)(3)
(To Prospectus dated July 14, 2014)	Registration No. 333-190798

 

692,815 Shares of Common Stock

This prospectus supplement (“Supplement”) modifies and supplements information contained in, and should be read in conjunction with, that certain prospectus, dated July 14, 2014 (“Prospectus”), of Adamis Pharmaceuticals Corporation (the “Company”). The Prospectus relates to the resale of up to 692,815 shares of our common stock pursuant to the exercise of previously issued warrants by the selling stockholders identified in the Prospectus, including their transferees, pledgees, donees or successors. The warrants have a current exercise price of $3.40 per share, subject to adjustments, and may be exercised during the period ending June 26, 2018 (the “Warrants”). The selling stockholders may, from time to time, sell, transfer, or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market, or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

This Supplement is being filed to disclose the transfer of securities of certain selling shareholders as provided in the Selling Shareholder table below. This Supplement is not complete without, and may not be delivered or used except in connection with, the original Prospectus and all supplements thereto.

The information attached to this Supplement modifies and supersedes, in part, the information in the Prospectus, as supplemented. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Supplement.

We may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire Prospectus and any amendments or supplements thereto carefully before you make an investment decision.

See “Risk Factors” beginning on page 8 of the Prospectus dated July14, 2014, for risk factors and information you should consider before you purchase shares.

SELLING SHAREHOLDERS

The Company has been by notified that certain securities previously registered to certain selling shareholders have been transferred. Specifically, the Selling Shareholder table is being amended to (i) reflect the transfer of warrants to purchase up to 65,360 shares of common stock from Brio Capital Master Fund Ltd. to Midsummer Small Cap Master, Ltd., (ii) reflect the transfer of warrants to purchase up to 60,000 shares of common stock from Pacific Capital Management, LLC to Midsummer Small Cap Master, Ltd., (iii) reflect the transfer of warrants to purchase up to 95,000 shares of common stock from Midsummer Small Cap Master, Ltd. to OTA LLC. The original Prospectus has not been updated or modified, and unless amended by this Prospectus Supplement all other information contained in the Selling Shareholder table, as contained in the July 14, 2014, Prospectus, is unaffected.

Name of Selling Stockholder	Number of Shares of Common Stock Beneficially Owned Prior to Offering			Number of Shares Offered (21)		Number of Shares of Common Stock Beneficially Owned After Offering
Brio Capital Master Fund Ltd. (1)		0			0		0
Midsummer Small Cap Master, Ltd. (2)		35,360	(3)		35,360		0
Pacific Capital Management, LLC (4)		70,719	(5)		70,719		0
OTA LLC (6)		95,000	(7)		95,000		0

(1)	Shaye Hirsch, director of Brio Capital Master Fund Ltd., has sole voting and dispositive power over these securities.
(2)	Joshua Thomas and Michel Amsalem have the power to vote and dispose of these securities.
(3)	Represents 35,360 shares initially issuable upon exercise of the Warrants.
(4)	Jonathan Glaser has voting and investment power over these securities
(5)	Represents 70,719 shares initially issuable upon exercise of the Warrants.
(6)	Ira M. Leventhal has voting and dispositive power with respect to these securities.
(7)	Represents 95,000 shares initially issuable upon exercise of the Warrants.